Allergy Clinical Trials 2023

Allergy Clinical Trials 2023

Allergy research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in allergy clinical trials today.

Allergy Clinical Trials

Here are the 6 most popular medical studies for allergy

Popular filter options for allergy trials

Food Allergy Clinical Trials

View 20 Food Allergy medical studies.

Allergy Clinical Trials With No Placebo

View 96 allergy medical studies that do not have a placebo group.

View More Allergy Trials

See another 66 many medical studies focused on allergy.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to allergy

What are the top hospitals conducting allergy research?

When it comes to cutting-edge clinical trials addressing allergies, several hospitals are at the forefront of innovation. Massachusetts General Hospital in Boston is currently conducting four active allergy trials and made history by recording their first trial in this field just last year, in 2021. In New Yorke allergy trials and made history by recording their first trial in this field just last year, in 2021. In New York City, the Icahn School of Medicine at Mount Sinai is also actively engaged with four ongoing allergy trials. Although they have yet to record any completed trials specifically for allergies, their expertise and dedication make them a vital player in the field.

Meanwhile, Western Sky Medical Research located in El Paso has three active allergy trials underway and an impressive track record of ten previously conducted investigations since their inaugural allergy trial debuted back in 2007. On the other hand, Novartis Investigative Sites both in Louisville and Baltimore may not have any recorded past or completed allergy trials but are currently contributing with two active studies each.

These top hospitals represent beacons of hope for individuals dealing with allergies across the country. With research efforts focused on understanding allergic reactions better and developing new treatments, these institutions play a crucial role in improving lives affected by this widespread condition. By pushing boundaries through innovative clinical trials, they aim to bring relief and advancements that will enhance our overall quality of life amidst allergen-filled environments that challenge us daily

Which are the best cities for allergy clinical trials?

Chicago, Illinois; Boston, Massachusetts; and New Yorkgo, Illinois; Boston, Massachusetts; and New York, New York emerge as the top cities for allergy clinical trials. In Chicago, there are 20 ongoing trials investigating treatments like iREACH CDS Tool, Prebiotic, and Tri-lipid skin barrier cream (Epiceram). Boston follows closely with 8 active trials focusing on Peanut SLIT-tablet, Ligelizumab 120 mg, and Segmental allergen challenge. Meanwhile, New York hosts 7 studies examining DBV1605 and Ligelizumab 120 mg among others. These cities provide individuals with allergies access to cutting-edge research and potential breakthroughs in treatment options.

Which are the top treatments for allergy being explored in clinical trials?

Allergy research is a field of ongoing exploration, with several promising treatments currently being studied in clinical trials. Leading the pack are sublingual immunotherapy (SLIT) and oral immunotherapy (OIT), both showing potential to revolutionize allergy treatment. SLIT involves placing allergen extracts under the tongue to desensitize the immune system, while OIT focuses on gradually increasing exposure to allergens through controlled ingestion. These innovative approaches offer hope for improved management and long-term relief for individuals suffering from allergies.

What are the most recent clinical trials for allergy?

Exciting advancements in allergy research have led to the emergence of several recent clinical trials. Ligelizumab, a medication being evaluated in Phase 3 trials at a dose of 120 mg, shows promise as a potential treatment for allergies. Another trial focuses on remibrutinib, which is undergoing Phase 2 testing at low doses with encouraging results. Additionally, researchers are exploring the effectiveness of oral challenges and peanut SLIT-tablets to better understand and manage allergies. In another study, investigators are evaluating Abrocitinib at a dosage of 100mg for its potential impact on allergic reactions. These clinical trials offer hope for improved treatments that can enhance the quality of life for individuals affected by allergies.

What allergy clinical trials were recently completed?

A noteworthy clinical trial has recently concluded, shedding light on advancements in the field of allergy treatment. In December 2020, MEDA Pharma GmbH & Co. KG successfully completed a trial for Treatment A (Dymista), which is a fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5. This significant milestone highlights ongoing efforts to enhance therapies for allergies and offers hope to individuals who suffer from these conditions.